TY - JOUR
T1 - Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
AU - Yamagishi, Yuko
AU - Kuwahara, Motoi
AU - Suzuki, Hidekazu
AU - Sonoo, Masahiro
AU - Kuwabara, Satoshi
AU - Yokota, Takanori
AU - Nomura, Kyoichi
AU - Chiba, Atsuro
AU - Kaji, Ryuji
AU - Kanda, Takashi
AU - Kaida, Ken Ichi
AU - Mutoh, Tatsuro
AU - Yamasaki, Ryo
AU - Takashima, Hiroshi
AU - Matsui, Makoto
AU - Nishiyama, Kazutoshi
AU - Sobue, Gen
AU - Kusunoki, Susumu
N1 - Funding Information:
Competing interests YY, HS, MS, KN, RK, TK, KK, TM, RY, MM, KN, GS report no disclosures. MK reports personal fees from Teijin, CSL Behring, Japan Blood Products Organization, Nihon and Takeda Pharmaceutical, outside the submitted work. SKuw reports personal fees from Teijin and CSL Behring, outside the submitted work. He serves as Associate Editor of Journal of Neurology, Neurosurgery, and Psychiatry, and Editorial Board member of Journal of the Neurological Sciences. TY reports other from Teijin during the conduct of the study and other from Teijin outside the submitted work. AC reports other from Teijin outside the submitted work. HT reports grants and other from Eisai, Mitsubishi Tanabe pharma, Sumitomo Dainippon, Teijin, Takeda Pharmaceutical, Daiichi-Sankyo, Otsuka, Astellas, JB and Kyowa Kirin outside the submitted work. He reports other from Pfizer, Ono and Fujimoto Pharmaceutical, AbbVie, Bristol Myers Squibb, Sanofi, Asahi Kasei Medical, Biogen outside the submitted work. SKus reports grants from Japan Agency for Medical Research and Development (AMED), Japan Society for the Promotion of Science, and Ministry of Health, Labour and Welfare of Japan, during the conduct of the study. He reports grants from Teijin, Japan Blood Products Organization, Nihon Pharmaceutical, personal fees from Teijin, Japan Blood Products Organization, Nihon Pharmaceutical and CSL Behring, outside the submitted work.
Funding Information:
Funding This work was supported by the Practical Research Project for Rare/ Intractable Diseases from the Japan Agency for Medical Research and Development (AMED, 16ek0109056h0003), Japan Society for the Promotion of Science (Grants-in-Aid for Scientific Research, 18H02745) and the Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grant on Rare and Intractable Diseases (Validation of Evidence-based Diagnosis and Guidelines, and Impact on QOL in Patients with Neuroimmunological Diseases)).
Publisher Copyright:
©
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Objective Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool. Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. Methods The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. Results The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. Conclusions The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes.
AB - Objective Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool. Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. Methods The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. Results The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. Conclusions The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85094184308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094184308&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2020-323960
DO - 10.1136/jnnp-2020-323960
M3 - Article
C2 - 33041261
AN - SCOPUS:85094184308
SN - 0022-3050
VL - 91
SP - 1339
EP - 1342
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 12
ER -
